ENDRA Life Sciences Inc.
NDRA
$3.86
$0.29188.19%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.85M | 5.63M | 5.71M | 5.52M | 6.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.98M | 9.60M | 10.36M | 10.52M | 12.38M |
| Operating Income | -7.98M | -9.60M | -10.36M | -10.52M | -12.38M |
| Income Before Tax | -8.82M | -9.57M | -9.89M | -10.06M | -11.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.82 | -9.57 | -9.89 | -10.06 | -11.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.82M | -9.57M | -9.89M | -10.06M | -11.89M |
| EBIT | -7.98M | -9.60M | -10.36M | -10.52M | -12.38M |
| EBITDA | -7.92M | -9.52M | -10.26M | -10.40M | -12.24M |
| EPS Basic | -152.52 | -142.99 | -- | -- | -- |
| Normalized Basic EPS | -95.33 | -89.37 | -- | -- | -- |
| EPS Diluted | -152.52 | -142.99 | -- | -- | -- |
| Normalized Diluted EPS | -95.33 | -89.37 | -- | -- | -- |
| Average Basic Shares Outstanding | 262.40K | 15.60K | -- | -- | -- |
| Average Diluted Shares Outstanding | 262.40K | 15.60K | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
